Biosimilars Market Growth Forecast 2025: Industry Trends, Market Size, and Projections

 The Business Research Company’s report on the Biosimilars Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.

 
 How are market drivers shaping the future growth trajectory of the biosimilars industry?
 The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market.
 
 Access Your Free Sample of the Global Biosimilars Market Report — Get Insights Now!
 https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp
 
 What is the estimated market size of the biosimilars sector by 2029, based on current forecasts?
 The biosimilars market size has grown rapidly in recent years. It will grow from $18.65 billion in 2024 to $21.95 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical R&D expenditure, increased healthcare expenditure, growing government initiatives, a strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration.
 
 The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $42.16 billion in 2029 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to the increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. Major trends in the forecast period include a focus on robust R&D activities for the development of effective and innovative drugs, on focus on M&A growth strategies, a focus on establishing strategic partnerships, a focus on increasing investments, and a focus on artificial intelligence.
 
 Gain Exclusive Market Insights — Customize Your Research Report Today For Fast Delivery!
 https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp
 
 Who are the top players in the biosimilars market?
 Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)
 
 What are the major trends in the biosimilars market?
 Major companies in the biosimilars market focus on developing innovative products to gain a competitive edge in the market. AMJEVITA is the first U.S. biosimilar to Humira, a medicine used by more than a million patients living with certain serious inflammatory diseases. For instance, in January 2023, Amgen Inc., a US-based biotechnology company, launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), which is now available in the US. AMJEVITA (40 mg) is available at a list price (wholesale acquisition cost) 55% below the current Humira list price. AMJEVITA is also available at a list price 5% below the current Humira list price.
 
 Which geography holds the highest biosimilars market share?
 North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Order Your Report Now For Swift Delivery
 https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report
 
 How do different segments contribute to the overall expansion of the biosimilars market?
 The biosimilars market covered in this report is segmented –
 
 1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others
 2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins
 3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications
 
 Subsegments:
 1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars
 2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars
 3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars
 4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars
 5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars
 6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics
 
 
 Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2807
 
 How is the biosimilars market defined?
 Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs.
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company